Vivoryon Therapeutics NV (WBO:VVYN) Total Stockholders Equity: €4.73 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:VVYN Vivoryon Therapeutics NV WBO:VVYN
16 GF Score
Price €1.12
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV Total Stockholders Equity?

Vivoryon Therapeutics NV WBO:VVYN 16 Total Stockholders Equity is €4.73 Mil as of Dec. 2025. GuruFocus rates WBO:VVYN with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Vivoryon Therapeutics NV's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €4.73 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vivoryon Therapeutics NV's Book Value per Share for the quarter that ended in Dec. 2025 was €0.16. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vivoryon Therapeutics NV's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.02.

Vivoryon Therapeutics NV  (WBO:VVYN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vivoryon Therapeutics NV's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.727-0)/29.614
=0.16

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vivoryon Therapeutics NV's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.064 + 0.044) / 4.727
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Total Stockholders Equity Related Terms

Vivoryon Therapeutics NV Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Total Stockholders Equity Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.56 26.51 26.28 7.88 4.73

Vivoryon Therapeutics NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.28 13.98 7.88 3.18 4.73
WBO:VVYN
16GF Score
Vivoryon Therapeutics NV WBO:VVYN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €4.73 Mil mean?
Vivoryon Therapeutics NV (WBO:VVYN) has a Total Stockholders Equity of €4.73 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vivoryon Therapeutics NV and its competitors.
Is Vivoryon Therapeutics NV's Total Stockholders Equity too high?
Vivoryon Therapeutics NV's current Total Stockholders Equity is €4.73 Mil. Overall, Vivoryon Therapeutics NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's Total Stockholders Equity compare to VRTX and REGN?
Vivoryon Therapeutics NV's Total Stockholders Equity of €4.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current Total Stockholders Equity is €4.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (WBO:VVYN) has a current Total Stockholders Equity of €4.73 Mil. The current Total Stockholders Equity is €4.73 Mil. Vivoryon Therapeutics NV's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Vivoryon Therapeutics NV (WBO:VVYN), the current Total Stockholders Equity is €4.73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
16GF Score

Get the complete analysis for WBO:VVYN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.12
Price